INVO Bioscience Overview
Valuation check: INVO's P/E ratio is -0.03, below the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow-0.03
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
INVO Bioscience (INVO) currently reports a P/E ratio of -0.03. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore INVO Bioscience's P/E ratio history and peer comparisons.
INVO Bioscience's P/E ratio of -0.03 is lower than the Healthcare sector average of 25.3. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates INVO Bioscience's market price to a fundamental measure such as earnings, sales, or book value. At -0.03, INVO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.03, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for INVO Bioscience, and consider following INVO for alerts when major investors trade the stock.
INVO Bioscience is classified in the Healthcare sector. On P/E ratio, it currently shows -0.03 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INVO with unrelated industries.
